RV 001 - RhoVac

Drug Profile

RV 001 - RhoVac

Alternative Names: RV 001 - RhoVac; RV 001V; RV001V - RhoVac

Latest Information Update: 06 Jul 2017

Price : $50

At a glance

  • Originator RhoVac
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 30 Mar 2017 Phase-I/II clinical trials in Prostate cancer in Denmark (SC) (NCT03199872)
  • 03 Nov 2016 RhoVac plans a phase IIb trial for cancer (in ex-non small cell lung cancer) (RhoVac website, November 2016)
  • 19 Oct 2016 RhoVac receives tentative approval for a patent application covering RV 001 from European Patent Office
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top